Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 8/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 6/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219713 | 0.85 | ATAD2 (0.45) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL10517587 | 0.85 | ATAD2 (0.45) | ATAD2PDK2PDK4PGRPDE3B | |
| Hydrochloric Acid SCHEMBL9559266 | 0.83 | ATAD2 (0.44) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL2490212 | 0.82 | PDK2 (0.45) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL2486621 | 0.82 | PDK2 (0.45) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL9831613 | 0.79 | PGR (0.48) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL2487418 | 0.79 | TDP1 (0.49) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL520415 | 0.76 | PDK2 (0.55) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL30539488 | 0.76 | PDK2 (0.55) | ATAD2PDK2PDK4PGRPDE3B | |
| SCHEMBL496554 | 0.76 | PDK2 (0.55) | ATAD2PDK2PDK4PGRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1966213-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| CN-101160312-A | Tricyclic azole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| WO-2008022747-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007068465-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
| US-4730003-A | Tricyclic compounds for treating heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1988-03-08 | — | — | US | disclosed |
| EP-0257334-A2 | Tricyclic benzotriazoles, process for their preparation and medicaments | Roche Diagnostics GmbH (DE) | 1988-03-02 | — | — | EP | disclosed |
| US-4710510-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-12-01 | — | — | US | disclosed |
| US-4695567-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them and method of using them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-09-22 | — | — | US | disclosed |
| US-4671803-A | PARTIAL OXIDATION PROCESS | TEXACO DEVELOPMENT CORP. (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0214592-A2 | Pyrrolobenzimidazoles, process for their preparation and medicaments containing these products | Roche Diagnostics GmbH (DE) | 1987-03-18 | — | — | EP | disclosed |
| EP-0189103-A2 | Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates | Roche Diagnostics GmbH (DE) | 1986-07-30 | — | — | EP | disclosed |
| EP-0186010-A1 | Pyrrolo benzimidazoles, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
| CN-85103724-A | The method for preparing novel pyrrolo-benzoglyoxaline | — | 1986-07-02 | — | — | CN | disclosed |
| EP-0161632-A2 | Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates | Roche Diagnostics GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | AAAS, CYP3A5, BRCA1 | ATAD2 4123/4885PDK2 3469/4885PDK4 3323/4885 |
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | ATAD2 4258/4885PDK2 633/4885PDK4 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.